

# INTERNATIONAL COOPERATION TREATY

GlaxoSmithKline

Corporate IP

Received BRENTFORD

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

GlaxoSmithKline  
Corporate IP

12 JUL 2004

Received NFSP

PCT

- 8 JUL 2004

To:

GIDDINGS, Peter John  
GLAXOSMITHKLINE, CIP  
980 Great West Road  
Brentford  
Middlesex TW8 9GS  
GRANDE BRETAGNE

ADMIN	MI
ON	UPDATED ON
ATTY CHECKED	

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing  
(day/month/year)

06.07.2004

Applicant's or agent's file reference  
JNR/PG4808

## IMPORTANT NOTIFICATION

International application No.  
PCT/EP 03/04402

International filing date (day/month/year)  
24.04.2003

Priority date (day/month/year)  
26.04.2002

Applicant

GLAXO GROUP LIMITED et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**


The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international  
preliminary examining authority:



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized Officer

Schmidbauer, A


Tel. +49 89 2399-8222



# PCT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>JNR/PG4808</b>	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. <b>PCT/EP 03/04402</b>	International filing date ( <i>day/month/year</i> ) <b>24.04.2003</b>	Priority date ( <i>day/month/year</i> ) <b>26.04.2002</b>
International Patent Classification (IPC) or both national classification and IPC <b>A61M15/00</b>		
Applicant <b>GLAXO GROUP LIMITED et al.</b>		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 7 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of    sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I    <input checked="" type="checkbox"/> Basis of the opinion</li> <li>II   <input type="checkbox"/> Priority</li> <li>III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV <input checked="" type="checkbox"/> Lack of unity of invention</li> <li>V   <input checked="" type="checkbox"/> Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input type="checkbox"/> Certain observations on the international application</li> </ul>		
Date of submission of the demand  <b>05.11.2003</b>	Date of completion of this report  <b>06.07.2004</b>	
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer  <b>Borowski, A</b>  Telephone No. +49 89 2399-2758	



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/EP 03/04402**

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, Pages**

1-46 as originally filed

**Claims, Numbers**

1-107 as originally filed

**Drawings, Sheets**

1-9 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  
☐ the language of publication of the international application (under Rule 48.3(b)).  
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.  
☐ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority in written form.  
☐ furnished subsequently to this Authority in computer readable form.  
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/EP 03/04402**

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 107

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):

☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 107 are so unclear that no meaningful opinion could be formed (*specify*):

**see separate sheet**

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the Standard.

☐ the computer readable form has not been furnished or does not comply with the Standard.

**IV. Lack of unity of invention**

1. In response to the invitation to restrict or pay additional fees, the applicant has:

☐ restricted the claims.

☐ paid additional fees.

☐ paid additional fees under protest.

☒ neither restricted nor paid additional fees.

2. ☐ This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/EP 03/04402**

---

☐ complied with.

☐ not complied with for the following reasons:

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

☐ all parts.

☒ the parts relating to claims Nos. 1-10, 30-106 .

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	1-10,30-106
	No: Claims	
Inventive step (IS)	Yes: Claims	1-10,30-106
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-10,30-106
	No: Claims	

2. Citations and explanations

**see separate sheet**

**Re Item III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

Claim 107 does not meet the requirements of Article 6 PCT in that the matter for which protection is sought is not clearly defined, as the claim contains a reference to the drawings. According to Rule 6.2(a) PCT, claims should not contain such references except where absolutely necessary, which is not the case here.

**Re Item IV**

**Lack of unity of invention**

The present application lacks unity (Rule 13 PCT), as 3 groups of inventions are claimed:

- 1) Claims 1-10, which essentially define a medicament dispenser, comprising: a housing, a medicament container, an electronic dose counter with a sensor and means for detecting changes in the performance of the sensor and for adjusting the operation of the dispenser to compensate for said changes;
- 2) Claims 11-14, which essentially define a medicament dispenser, comprising: a housing, a medicament container, an electronic dose counter with a sensor and means for resisting deposition of contaminants;
- 3) Claims 15-29, which essentially define a medicament dispenser, comprising: a housing, a medicament container, an electronic dose counter with a sensor and means for removing contaminants;

Claims 30-106 are dependent on any of said 3 groups.

The common matter between any two groups of invention is at most a medicament dispenser, comprising: a housing, a medicament container and an electronic dose counter with a sensor.

Said matter is not novel over the disclosure of document US5794612 (see Column 2, Lines 9-24; Column 3, Lines 22-24; Fig. 1), for example.

✓ 15/12

Therefore, according to Rule 13(1) PCT the requirement of unity is not fulfilled, because there are no common special technical features(Rule 13(2) PCT).

**Re Item V**

**Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

*Intention*  
V.1 Document US5544647 (cited on page 2 of the description) is regarded as being the closest prior art to the subject-matter of claim 1, and shows a medicament dispenser comprising a housing having an outlet; a medicament container locatable within said housing; and an electronic dose counter associated with said outlet, wherein said dose counter comprises a first sensor for directly detecting a medicament release dispensable from said medicament container through said outlet.

The subject-matter of claim 1 differs from this known medicament dispenser in that there are provided means for detecting changes in the performance of the sensor attributable to contamination or degradation and for adjusting the operation of the dispenser to compensate, at least in part, for said changes.

The subject-matter of claim 1 is therefore new (Article 33(2) PCT).

The problem to be solved by the present invention may be regarded as how to avoid false readings of a dose counter.

The solution to this problem proposed in claim 1 of the present application is considered as involving an inventive step (Article 33(3) PCT), as it is neither disclosed nor suggested by any related prior art.

Claims 2-10 and 30-106 are dependent on claim 1 and as such also meet the requirements of the PCT with respect to novelty and inventive step.

V.2 The International Patent Application No. PCT/EP01/12108, published as WO 02/36190 and filed on 19.10.2001 forms an earlier application, which destroys novelty of claims 1-5, 10 and 30-106 if the present application enters the regional phase. ✓ 15/8

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP03/04402

- V.3 The independent claim 1 should have been drafted in the two-part form, as normally required by Rule 6.3(b) PCT, with those features known in combination from the prior art (cf. 1st paragraph of V.1 above) being placed in the preamble (Rule 6.3(b)(I) PCT) and with the remaining features being included in the characterising part (Rule 6.3(b)(ii) PCT).
- V.4 The features of the claims should have been provided with reference signs placed in parentheses (Rule 6.2(b) PCT).